Effect of extended-release isosorbide mononitrate one hour after dosing in patients with stable angina pectoris. IMDUR Study Group

The American Journal of Cardiology
S P Glasser

Abstract

The effect of extended-release isosorbide mononitrate (ER-ISMN) on exercise tolerance 1 hour after dosing was compared with that of placebo in a multicenter, randomized, double-blind study of 151 patients with stable effort-induced angina. During a 9- to 24-day placebo run-in, patients underwent Bruce protocol baseline exercise tolerance tests, after which they received ER-ISMN or placebo for 5 days. ER-ISMN patients took 60 mg each morning for the first 4 days and 120 mg on the morning of the fifth day. One hour after dosing, ER-ISMN patients had a significantly greater increase in total exercise time (days 1 to 4: 5 +/- 53 seconds; day 5: 53 +/- 58 seconds) than the placebo-treated patients (days 1 to 4: 14 +/- 37 seconds; day 5: 21 +/- 48) (p <0.001). The times to development of angina and 1-mm ST-segment depression were significantly longer in the ER-ISMN group than in the placebo group. The difference between the groups in mean time to onset of angina was 34 seconds after the 60-mg dose (p = 0.004) and 49 seconds after the 120-mg dose (p <0.001). The mean time to development of a 1-mm ST-segment depression was 51 and 61 seconds longer after the 60-mg and 120-mg ER-ISMN doses, respectively, than after placebo (p <0.001). Tr...Continue Reading

References

Aug 1, 1992·The American Journal of Cardiology·G IronsonG M Segall
Dec 8, 1991·The New England Journal of Medicine·A C YeungA P Selwyn
Mar 15, 1989·Journal of the American College of Cardiology·H DeMots, S P Glasser
Jul 1, 1984·American Heart Journal·G SpecchiaA Mussini
Jan 1, 1993·Journal of Cardiovascular Pharmacology·W Kiowski, S Osswald
Jan 1, 1994·Cardiology·J E Muller, B Mangel
Oct 15, 1993·The American Journal of Cardiology·J O Parker
Dec 1, 1993·The American Journal of Cardiology·S G ChrysantR Casareto
Dec 15, 1993·The American Journal of Cardiology·M D BoltwoodJ Giacomini
Feb 4, 1993·The New England Journal of Medicine·V K SomersF M Abboud

❮ Previous
Next ❯

Citations

Mar 11, 1999·The American Journal of Cardiology·C M WebbP Collins
Apr 1, 2017·Journal of Cardiovascular Pharmacology and Therapeutics·Santosh K PadalaPeter P Toth

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.